Implications of the diabetes control and complications trial for persons with non-insulin-dependent diabetes mellitus

Southern Medical Journal

Volumn 90, Issue 3, 1997, Pages 268-282

  Vinik, Aaron I ^a,b   Richardson, Donald W ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b Diabetes Institutes Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; ANTILIPEMIC AGENT; BIGUANIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETES CONTROL; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MANAGED CARE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; ONSET AGE; ORAL DRUG ADMINISTRATION; OUTCOMES RESEARCH; WEIGHT GAIN;

ADULT; AGE FACTORS; BLOOD GLUCOSE; CAUSE OF DEATH; CLINICAL TRIALS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DIABETIC NEUROPATHIES; DIABETIC RETINOPATHY; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; INSULIN; INSULIN RESISTANCE; INTERVENTION STUDIES; OBESITY; RISK FACTORS;

EID: 0030978695     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007611-199703000-00001     Document Type: Article

References (78)

1. Harris MI, Klein T, Welborn TA, et al: Onset of NIDDM occurs at least 4-7 years before clinical diagnosis. Diabetes Care 1992; 15:1-5
2. Zimmett PZ, Tuomi T, Mackay IR, et al: Latent autoimmune diabetes mellitus in adults (LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency. Diabetic Med 1994; 3:299-303
3. Klein R, Klein BEK, Moss SE: Epidemiology of proliferative diabetic retinopathy. Diabetes Care 1992; 15:1875-1891
4. Pirart J: Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973. Diabetes Care 1978; 1:168-188, 252-263
5. Wang PH, Lau J, Chalmers TC: Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. Lancet 1993; 341:1306-1309
6. Bilous RW, Mauer SM, Sutherland DE, et al: The effects of pancreas transplantation on the glomerular structure of renal allografts in patients with insulin-dependent diabetes. N Engl J Med 1989; 321:80-85
7. Garber AJ: Damage control may now begin (Editorial commentary). Clin Diabetes 1993; 11:121-122
8. Acton K, Rith-Nijarian S, Ghodes D: Implications of the Diabetes Control and Complications Trial. Provider 1993; 18:185-187
9. Marks J: What price metabolic control? (Editorial) Clin Diabetes 1993; 11:144
10. Raskin P: The DCCT - finally! (Editorial) J Diabetes Complications 1993; 2:214-215
11. American Diabetes Association: Metabolic control matters nationwide translation of the Diabetes Control and Complications Trial: analysis and recommendations. Clin Diabetes 1993; 11:91, 95-96
12. Guidelines for the Care of Patients With Diabetes. Alexandria, Va, American Diabetes Association, 1994
13. Eastman RC, Siebert CW, Harris M, et al: Clinical review 51: implications of the Diabetes Control and Complications Trial. J Clin EndocrinolMetab 1993; 77:1105-1107
14. Lasker RD: The Diabetes Control and Complications Trial. implications for policy and practice (Editorial). N Engl J Med 1993; 329:1035-1036
15. Kennedy WR, Navarro X, Goetz FC, et al: Effects of pancreatic transplantation on diabetic neuropathy. N Engl J Med 1990; 322:1031-1037
16. The Diabetes Control and Complications Trial Research Group: The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 1995; 122:561-568
17. Vinik AI, Milicevic Z, Pittenger GL: Beyond glycemia. Diabetes Care 1995; 18:1037-1041
18. Vinik AI, Newlon PG, Lauterio TJ, et al: Nerve survival and regeneration in diabetes. Diabetes Rev 1995; 3:139-157
19. Pittenger GL, Liu D, Vinik AI: The toxic effects of serum from patients with type I diabetes mellitus on mouse neuroblastoma cells: a new mechanism for development of autonomie neuropathy. Diabetic Med 1993; 10:925-932
20. Pittenger GL, Milicevic Z, Vinik AI: Autoimmune mechanisms of diabetic neuropathy. Diabetes Mellitus: A Fundamental and Clinical Text. LeRoith D, Olefsky JM, Taylor SI (eds). Philadelphia, Lippincott-Raven, 1996, p 751
21. Pittenger GL, Liu D, Vinik AI: The neuronal toxic factor in serum of type 1 diabetic patients is a complement-fixing autoantibody. Diabetic Med 1995; 12:380-386
22. Nolan RD, Vinik AI: Pathogenesis of platelet dysfunction in diabetes. Diabetes Mellitus: A Fundamental and Clinical Text. LeRoith D, Olefsky JM, Taylor SI (eds). Philadelphia, Lippincott-Raven, 1996, p 832
23. Liuzzi FJ, Depto AS: Neuropathy: growth factors and nerve regeneration. Diabetes Mellitus: A Fundamental and Clinical Text. LeRoith D, Olefsky JM, Taylor SI (eds). Philadelphia, Lippincott-Raven, 1996, p 766
24. Reaven GM: The role of insulin resistance in human disease. Diabetes 1988; 37:1595-1607
25. Nathan DM: Long-term complications of diabetes mellitus. N Engl J Med 1993; 328:1676-1685
26. Jarrett RJ, McCartney P, Keen H: The Bedford Study: ten year mortality rates in newly diagnosed diabetics, borderline diabetics, and normoglycemic controls and risk indices for coronary heart disease in borderline diabetics. Diabetologia 1992; 22:79-84
27. Kuusisto J, Mykkanen L, Pyorala K, et al: NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 1994; 43:960-967
28. 1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 1995; 44:968-983
29. Welborn TA, Wearne K: Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care 1979; 2:154-160
30. Ducimetiere P, Eschwège E, Papoz L, et al: Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population. Diabetologia 1980; 19:205-210
31. Pyorala K: Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care 1979; 2:131-141
32. Fontbonne A, Charles MA, Thibult N, et al: Hyperinsulinemia as a predictor of coronary heart disease mortality in a healthy population: the Paris Prospective Study, 15-year follow-up. Diabetologia 1991; 34:356-361
33. Eschwège E, Richard JL, Thibult N, et al: Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels. the Paris Prospective Study, ten years later. Harm Metab Res 1985; 15(suppl):41-46
34. Fontbonne AM, Eschwège EM: Insulin and cardiovascular disease. Paris Prospective Study. Diabetes Care 1991; 14:461-469
35. Pyorala K, Savolainen E, Kaukola S, et al: Plasma insulin as coronary heart disease factor: relationship to other risk factors and predictive value during 91/2 year follow-up of the Helsinki policemen study population. Acta Med Scand 1985; 701 (suppl):38-52
36. Haffner SM, Stern MP, Hazuda HP, et al: Cardiovascular risk factors in confirmed prediabetic individuals. does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990; 263:2893-2898
37. Cullen K, Stenhouse NS, Wearne K, et al: Multiple regression analysis of risk factors for cardiovascular disease and cancer mortality in Busselton, Western Australia. 13 year study. J Chronic Dis 1983; 36:371-377
38. Collins VR, Dowse GK, Zimmet PZ, et al: Serum insulin and ECG abnormalities suggesting coronary heart disease in the population of Mauritius and Nauru: cross-sectional and longitudinal associations. J Clin Epidemiol 1993; 46:1373-1393
39. Liu QZ, Knowler WC, Nelson RG, et al: Insulin treatment, endogenous insulin concentration, and ECG abnormalities in diabetic Pima Indians. Diabetes 1992; 41:1141-1150
40. Stout RW, Buchanan KD, Vallance-Owen J: The relationship of arterial disease and glucagon metabolism in insulin-treated chickens. Atherosclerosis 1973; 18:153-162
41. Sato Y, Shiraishi S, Oshida Y, et al: Experimental atherosclerosis-like lesions induced by hyperinsulinism in Wistar rats. Diabetes 1989; 38:91-96
42. Stout RW, Buchanan KD, Vallance-Owen J: Arterial lipid metabolism in relation to blood glucose and plasma insulin in rats with streptozotocin-induced diabetes. Diabetologia 1972; 8:398-410
43. King GL, Davidheiser S, Banskota N, et al: Insulin receptors and actions on vascular cells. hypertension as an insulin-resistant disorder. Genetic Factors and Cellular Mechanisms. Smith U (ed). Amsterdam, Elsevier, 1991, p 183
44. Ferrannini E, Harrner SM, Nitchell BD, et al: Hyperinsulinemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia 1991; 34:416-422
45. Manninen V, Elo MO, Frick MH, et al: Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988; 260:641-651
46. Assman G, Shulte H; Triglycerides and atherosclerosis: results from the Prospective Cardiovascular Münster Study. Atherosclerosis Rev 1991; 22:51-57
47. DCCT Research Group: The Diabetes Control and Complications Trial (DCCT): design and methodologic considerations for the feasibility phase. Diabetes 1986; 35:530-545
48. Medical Management of Non-Insulin-Dependent (Type II) Diabetes. Alexandria, Va, American Diabetes Association, 1994
49. Helmrich SP, Ragland DR, Leung RW, et al: Physical activity and reduced occurrence of non-insulin-dependent diabetes mellitus. N Engl J Med 1991; 325:147-152
50. Manson JE, Colditz GA, Stampfer MJ, et al: A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med 1991; 151:1141-1147
51. Eriksson KF, Lindgarde F: Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. Diabetologia 1991; 34:891-898
52. Hadden DR, Blair AL, Wilson EA, et al: Natural history of diabetes presenting age 40-69 years: a prospective study of the influence of intensive dietary therapy. Q J Med 1986; 59:579-598
53. Nathan DM, Roussell A, Godine JE: Glyburide or insulin for metabolic control in non-insulin dependent diabetes mellitus. Ann Intern Med 1988; 108:334-340
54. Rains SGH, Wilson GA, Richmond W, et al: The effect of glibenclamide and metformin on serum lipoproteins in type 2 diabetes. Diabetic Med 1988; 5:653
55. Glaser B, Leibovich G, Nesher R, et al: Improved beta-cell function after intensive insulin treatment in severe non-insulin-dependent diabetes. Acta Endocrinol Copenh 1988; 118:365-373
56. Andrews WJ, Vasquez B, Nagulesparan M, et al: Insulin therapy in obese, non-insulin-dependent diabetes induces improvements in insulin action and secretion that are maintained for two weeks after insulin withdrawal. Diabetes 1984; 33:634-642
57. Garvey WT, Olefsky JM, Griffin J, et al: The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes 1985; 34:222-234
58. Firth RG, Bell PM, Rizza RA: Effect of tolazamide and exogenous insulin on insulin action in patients with non-insulin dependent diabetes mellitus. N Engl J Med 1986; 314:1280-1286
59. Yki-Jarvinen H, Kauppila M, Kujansuu E, et al: Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1992; 327:1426-1433
60. Henry RR, Gumbiner B, Ditzler T, et al: Intensive conventional insulin therapy for type II diabetes. Diabetes Care 1993; 16:21-31
61. Jennings AM, Lewis KS, Murdoch S, et al: Randomized trial comparing continuous subcutaneous insulin infusion and conventional insulin therapy in type II diabetic patients poorly controlled with sulfonylureas. Diabetes Care 1991; 14:738-744
62. Pettit DJ, Lisse JR, Knowler WC, et al: Development of retinopathy and proteinuria in relation to plasma:glucose concentrations in Pima Indians. Lancet 1980; 2:1050-1052
63. Jarrett RJ, Keen H: Hyperglycaemia and diabetes mellitus. Lancet 1976; 2:1009-1012
64. Teuscher A, Schnell H, Wilson PWF: Incidence of diabetic retinopathy and relationship to baseline plasma glucose and blood pressure. Diabetes Care 1988; 11:246-251
65. Klimt CR, Knatterud GL, Meinert CL, et al: The University Group Diabetes Program: a study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 1970; 19(suppl):789-830
66. UK Prospective Diabetes Study Group: UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia 1991; 34:877-890
67. Turner R, Cull C, Holman R: United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med 1996; 124:136-145
68. Abraira C, Emanuele N, Colwell J, et al: Glycemic control and complications in type II diabetes. Diabetes Care 1992; 15:1560-1571
69. Colwell JA: The feasibility of intensive insulin management in non-insulin-dependent diabetes mellitus. implications of the Veterans Affairs Cooperative Study on glycemic control and complications in NIDDM. Ann Intern Med 1996; 124:131-135
70. Haupt E, Laube F, Loy H, et al: Secondary failures in modern therapy of diabetes mellitus with blood glucose lowering sulfonamides. Med Klin 1977; 72:1529-1536
71. DCCT Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. N Engl J Med 1993; 329:977-986
72. Scarlett JA, Gray RS, Griffin J, et al: Insulin treatment reverses in the insulin resistance of type II diabetes mellitus. Diabetes Care 1982; 5:353
73. Nathan DM: Modern management of insulin-dependent diabetes mellitus. Med Clin North Am 1988; 72:1365-1378
74. Vinik AI, Mitchell BD, Leichter SB, et al: Epidemiology of the complications of diabetes. Diabetes: Clinical Science in Practice. Leslie RDG, Robbins DC (eds). Cambridge, England, Cambridge University Press, 1995, p 221
75. Stout RW: Insulin and atheroma. Diabetes Care, 1990; 13:631-654
76. Ohkubo Y, Kishikawa H, Araki E, et al: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28:103-117
77. Klein R, Klein BE, Moss SE, et al: The Wisconsin epidemiologic study of diabetic retinopathy. prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984; 102:527-532
78. Vinik AI, Newlon P, Milicevic Z, et al: Diabetic neuropathies: an overview of clinical aspects. Diabetes Mellitus: A Fundamental and Clinical Text. LeRoith D, OlefskyJM, Taylor SI (eds). Philadelphia, Lippincott-Raven, 1996, p 737